REPL Replimune Group Inc.

16.7
-0.51  -3%
Previous Close 17.21
Open 17.11
Price To Book 4.06
Market Cap 528,825,239
Shares 31,666,182
Volume 50,755
Short Ratio
Av. Daily Volume 71,678
Stock charts supplied by TradingView

NewsSee all news

  1. Replimune Announces Proposed Public Offering

    BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public

  2. Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update

    RP1: Clinical data presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) confirmed expected safety profile and mechanism of action: Efficacy data supports ongoing and expanded

  3. Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

    Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types Mechanism of action confirmed for RP1 alone and in combination with Opdivo Biomarker

  4. Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    WOBURN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host

  5. Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

    First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi's Libtayo® in CSCC New clinical trial planned of RP1 as monotherapy in organ transplant patients

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 further data due 2020.
RP1 and nivolumab
Solid tumors
Phase 2 commencement of enrolment announced October 15, 2019.
RP1 and cemiplimab
Cutaneous squamous cell carcinoma (CSCC)
Phase 1 commencement of enrolment announced October 24, 2019.
RP2 and nivolumab
Solid tumors

Latest News

  1. Replimune Announces Proposed Public Offering

    BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public

  2. Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update

    RP1: Clinical data presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) confirmed expected safety profile and mechanism of action: Efficacy data supports ongoing and expanded

  3. Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

    Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types Mechanism of action confirmed for RP1 alone and in combination with Opdivo Biomarker

  4. Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    WOBURN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host

  5. Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

    First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi's Libtayo® in CSCC New clinical trial planned of RP1 as monotherapy in organ transplant patients

  6. Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    WOBURN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that data with the

  7. Replimune to Present at Chardan's 3rd Annual Genetic Medicines Conference

    WOBURN, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert